Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, the company is involved in the integrated discovery, development, and manufacturing services for small and large molecules. It serves customers in approximately 120 countries. The company was incorporated in 1978 and is headquartered in Bengaluru, India.
Stock data | 2023 | Change |
---|---|---|
Price | $4.06 | N/A |
Market Cap | $4.85B | N/A |
Shares Outstanding | 1.19B | 0.17% |
Employees | 16.55K | N/A |
Shareholder Equity | 224.89B | 137.47% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | 1.05 | N/A |
P/S Ratio | 3.72 | N/A |
P/B Ratio | 0.02 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0003 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $1.30B | N/A |
Earnings | $76.65M | N/A |
EPS | 3.87 | N/A |
Earnings Yield | 0.9522 | N/A |
Gross Margin | 0.6646 | N/A |
Operating Margin | 0.1293 | N/A |
Net income margin | 0.0588 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $6.20B | N/A |
Total Debt | $2.15B | N/A |
Cash on Hand | $338.99M | N/A |
Debt to Equity | 0.0157 | 13.92% |
Cash to Debt | 0.1578 | -59.36% |
Current Ratio | $1.45 | -33.82% |